Institute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing City, Jiangsu Province, China.
Centre for Nephrology, University College London (UCL) Medical School, Royal Free Campus, UK.
Int J Biol Sci. 2017 Sep 5;13(9):1118-1125. doi: 10.7150/ijbs.21140. eCollection 2017.
Microparticles (MPs) are a type of extracellular vesicles (EVs) shed from the outward budding of plasma membranes during cell apoptosis and/or activation. These microsized particles then release specific contents (e.g., lipids, proteins, microRNAs) which are active participants in a wide range of both physiological and pathological processes at the molecular level, e.g., coagulation and angiogenesis, inflammation, immune responses. Research limitations, such as confusing nomenclature and overlapping classification, have impeded our comprehension of these tiny molecules. Diabetic nephropathy (DN) is currently the greatest contributor to end-stage renal diseases (ESRD) worldwide, and its public health impact will continue to grow due to the persistent increase in the prevalence of diabetes mellitus (DM). MPs have recently been considered as potentially involved in DN onset and progression, and this review juxtaposes some of the research updates about the possible mechanisms from several relevant aspects and insights into the therapeutic perspectives of MPs in clinical management and pharmacological treatment of DN patients.
微粒(MPs)是细胞凋亡和/或激活时质膜向外出芽脱落产生的一种细胞外囊泡(EVs)。这些微颗粒随后释放出特定的内容物(例如脂质、蛋白质、microRNAs),这些内容物在分子水平上积极参与广泛的生理和病理过程,例如凝血和血管生成、炎症、免疫反应。研究局限性,如命名混乱和分类重叠,阻碍了我们对这些微小分子的理解。糖尿病肾病(DN)目前是全球导致终末期肾病(ESRD)的最大病因,由于糖尿病(DM)患病率持续增加,其对公共健康的影响将继续增加。MPs 最近被认为可能与 DN 的发生和进展有关,本综述从几个相关方面对比了一些关于 MPs 可能机制的研究进展,并探讨了 MPs 在 DN 患者的临床管理和药物治疗中的治疗前景。